Breaking News

Xcelience to Develop and Manufacture DEA Schedule I Drug Products

Clinicians continue to find potential therapeutic indications for Schedule I drug substances

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Xcelience, a CDMO located in Tampa, FL, has received approval from the Federal Drug Enforcement Agency (DEA) to develop and manufacture Schedule I controlled substances in their facilities. Schedule I substances are “considered the most dangerous class of drugs,” according to the DEA website. Xcelience has a long history of working with DEA controlled substances and this license extension completes their approval to now handle both analytical and manufacturing of the full spectrum of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters